Alexion Pharma (ALXN) to be acquired by AstraZeneca (AZN) for $175 per share

   

 

** ALXN **

 

AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.

Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.

AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). Alexion has exhibited skilful commercial execution in building its 'blockbuster' C5 franchise. The success of the franchise is demonstrated by the effective transition of over 70% of PNH patients from Soliris to Ultomiris in less than two years of launch in its key markets, including the US, Japan and Germany, as well as the strong pipeline of additional indications for Ultomiris.

Immediately earnings-accretive and value-enhancing acquisition, in line with stated capital-allocation priorities - The acquisition is expected to deliver robust and sustainable accretion to AstraZeneca's core earnings per share (EPS) from the outset, with double-digit percentage accretion anticipated in the first three years following the completion of the acquisition.

Portola (PTLA) to be acquired by Alexion (ALXN) for $18 /sh

Alexion Pharmaceuticals announced Tuesday that it would spend $1.4 billion to acquire Portola Pharmaceuticals, which sells a medicine called Andexxa used to stop life-threatening bleeding in patients who have been given certain anticoagulants.

   

 

Achillion Pharma (ACHN) to be acquired by Alexion (ALXN)

  

 

Achillion Pharma to be acquired by Alexion (ALXN) for $6.30/share in cash + CVRs worth up to $2.00/share
To be acquired by Alexion (ALXN) for an all-cash initial consideration of approx. $930 mln, or $6.30/share; potential additional contingent considerations, which hinge on clinical and regulatory developments such as FDA approval of danicopan and ACH-5228 Phase 3 initiation, could elevate the amount payable to co's shareholders to $8.30/share. Alexion looks forward to applying its "development expertise" to co's oral Factor D inhibitors in an endeavor to unlock the approach's potential and deliver benefits to patients. The stock moves to its highest levels in almost three years.

**  ACHN  **

 

Alexion Pharma (ALXN) reported earnings on Mon 4 Feb 2019 (b/o)

** charts after earnings **

 

Alexion Pharma beats by $0.30, beats on revs; guides FY19 EPS above consensus, revs below consensus

• Reports Q4 (Dec) earnings of $2.14 per share, excluding non-recurring items, $0.30 better than the S&P Capital IQ Consensus of $1.84; revenues rose 24.1% year/year to $1.13 bln vs the $1.06 bln S&P Capital IQ Consensus.
• SOLIRIS net product sales were $976.7 million, compared to $791.9 million in the fourth quarter of 2017, representing a 23 percent increase. SOLIRIS volume increased 28 percent year-over-year.
• Co issues guidance for FY19, sees EPS of $9.10-9.30 vs. $8.80 S&P Capital IQ Consensus; sees FY19 revs of $4.625-4.7 bln vs. $4.75 bln S&P Capital IQ Consensus.

Earnings this week : Feb. 4 - 8, 2019 (wk 6)

Earnings expected this week:

Monday (Feb 4)

• Morning: ALXN CLX ON SYY
• Afternoon: AVB FN GILD GOOG GLUU HIG LM STX

Tuesday (Feb 5)

• Morning: ADM AME ARMK BDX CHD CNC EL EMR ENR INGR IT LII LITE RL 
• Afternoon: ALL APC APU CB CERN DATA DIS DOX  EA MANH  MCHP MODN  MTSI MYGN MXL OI  PAA  PAYC SAVE SCSC  SFLY   SNAP SWKS TCS  TENB ULTI USNA VNOM VRTX ZEN

Wednesday (Feb 6)

• Morning:  ABG BSX BCO CSTE CPRI CTSH CMI ELAN FDC FDV GM HUM LLY  NYT REGN  SPOT TRVG  TTWO 
• Afternoon: ACLS AEL AHL AINV AOSL BLKB CCK CCMP CDAY CENT CINF CMG CSGS CUB CUZ DHT ECHO EGP ELY ENS ENSG FEYE FLO FLT FORM FTNT GBDC GPRO HQY ICHR IRBT KNL LCI LNC MC MET MTCH MTRX NEWR NOV NTGR NTR NXPI ORLY OSUR PAHC PCTY PRU PSDO PSEC RGLD RYN SONO TRMB TTGT TTMI TWO UHAL VVV WERN ZNGA

Wed pm/Thur am (vol) https://finviz.com/screener.ashx?v=211&t=ACLS,AEL,AHL,AINV,AOSL,BLKB,CCK,CCMP,CDAY,CENT,CINF,CMG,CSGS,CUB,CUZ,DHT,ECHO,EGP,ELY,ENS,ENSG,FEYE,FLO,FLT,FORM,FTNT,GBDC,GPRO,HQY,ICHR,IRBT,KNL,LCI,LNC,MC,MET,MTCH,MTRX,NEWR,NOV,NTGR,NTR,NXPI,ORLY,OSUR,PAHC,PCTY,PRU,PSDO,PSEC,RGLD,RYN,SONO,TRMB,TTGT,TTMI,TWO,UHAL,VVV,WERN,ZNGA,ADNT,ADS,AMAG,ANDX,ARW,BCE,BR,BSIG,BV,CAH,CDW,CEIX,CNHI,COR,DNKN,DTE,EIGI,EPC,FCAU,GRA,GRUB,HAIN,HBI,ICE,K,LABL,LCII,LH,MAC,MAS,MD,MMS,MPC,MPLX,MPW,ODFL,PAG,PBH,PENN,PM,PRLB,PTEN,SEE,SNA,SNY,SPB,SPGI,TGI,TKR,TMUS,TPR,TSN,TWTR,VIRT,VSTO,WLTW,WMS,WWE,YUM&ta=0&o=-volume

Thursday (Feb 7)

• Morning: ADNT ADS AMAG ANDX ARW BCE BR BSIG BV CAH CDW CEIX CNHI COR DNKN DTE EIGI EPC FCAU GRA GRUB HAIN HBI ICE K LABL LCII LH MAC MAS MD MMS MPC MPLX MPW ODFL PAG PBH PENN PM PRLB PTEN SEE SNA SNY SPB SPGI TGI TKR TMUS TPR TSN TWTR VIRT VSTO WLTW WMS WWE YUM
• Afternoon: ATEN ATGE ALNY ASYS ANGI MT ATHN BECN BHE BKH CARB CSL CBL CCS COLM OFC DXC EGAN EHC ESE EEFT EXPE FISV FSCT FTV FET FWRD G HUBG IAC KN LGND MTW MCFT MAT MTD MOBL MHK MSI NCR UEPS NR NWSA NUAN OMCL CNXN PMT POWI PRI PRO QRVO QNST RPD RSG SGEN SKX SWI SYNA TDC TBI USX VRSN VVI VSAT VRTU VCRA WTS WU ZAYO 

Friday (Feb 8)

• Morning: ARNC AVA BPL CAE CBOE CLF COTY ESNT EXC GT GRC EAF HAS IMGN PCG PSX  PSXP RDN UNVR VTR 

=Alexion Pharma (ALXN) receives FDA approval for Soliris

Alexion Pharma receives FDA approval for Soliris 

• Co announced the FDA approved Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
• In the Phase 3 REGAIN study and its ongoing open-label extension study, Soliris demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms, which can include difficulties seeing, walking, talking, swallowing and breathing. 
• These patients are at an increased risk of disease exacerbations and crises that may require hospitalization and intensive care and may be life-threatening.
• These patients represent approximately 5-10% of all patients with MG.

Earnings this week : Oct 23 - 27, 17 (wk 43)

=Alexion Pharma (ALXN) reported earnings on Thur 27 July 2017 (b/o)

Alexion Pharma beats by $0.30, beats on revs; raises FY17 EPS above consensus :

• Reports Q2 (Jun) earnings of $1.56 per share, $0.30 better than the Capital IQ Consensus of $1.26; revenues rose 21.1% year/year to $912 mln vs the $846.15 mln Capital IQ Consensus.
• Co raises guidance for FY17, sees EPS of $5.40-5.55 vs. $5.33 Capital IQ Consensus Estimate, compared to $5.10-5.30 prior
• Co raises guidance for FY17 - sees revs of $3.45-3.53 bln vs. $3.47 bln Capital IQ Consensus Estimate, compared to $3.4-3.5 bln prior